16634-88-1

Usage

Uses

Used in Organic Synthesis:
5-BROMO-3-NITROSALICYLALDEHYDE 97 is used as a reagent in organic synthesis for its unique chemical properties. The presence of bromo and nitro groups allows it to participate in a variety of chemical reactions, making it a valuable component in the construction of organic compounds.
Used in Laboratory Research:
5-BROMO-3-NITROSALICYLALDEHYDE 97 is used as a research tool in laboratories, where its specific chemical characteristics can be explored and utilized in the development of new compounds and materials. Its reactivity and stability under certain conditions make it an important substance for scientific investigation.
Used in Industrial Processes:
In the industrial sector, 5-BROMO-3-NITROSALICYLALDEHYDE 97 is employed in the production of various chemical products. Its role as a reagent in industrial processes is crucial for the synthesis of complex organic molecules, which can be used in a wide range of applications, from pharmaceuticals to materials science.
Safety and Storage:
Due to its potential safety risks, 5-BROMO-3-NITROSALICYLALDEHYDE 97 should be handled with care, following the guidelines provided in its Material Safety Data Sheet. It is essential to store 5-BROMO-3-NITROSALICYLALDEHYDE 97 under specific conditions to ensure its stability and efficacy, preventing any adverse effects on its performance in chemical reactions.

InChI:InChI=1/C7H4BrNO4/c8-5-1-4(3-10)7(11)6(2-5)9(12)13/h1-3,11H

Upstream product

• 1761-61-1 5-bromosalicyclaldehyde 
• 90-02-8 salicylaldehyde 
• 5274-70-4 3-nitrosalicylic aldehyde 
• 128872-69-5 {Cu(C₇H₃BrNO₄)2dpy2} 

Downstream Products

• 13034-70-3 6-bromo-1',3',3'-trimethyl-8-nitro-1',3'-dihydro-spiro[chromene-2,2'-indole] 
• 99833-63-3 C₁₉H₁₅BrN₂O₅ 
• 671788-48-0 5-bromo-7,8-dibenzyloxyquinoline 
• 98592-10-0 5-bromo-2-hydroxy-3-nitro-cis-cinnamic acid 
• 681850-07-7 C₂₆H₁₉BrN₂O₄ 
• 329070-67-9 (CH₂NCHC₆H₂(NO₂)BrOH)2 

Relevant academic research and scientific papers

Campestarenes: New building blocks with 5-fold symmetry

Campestarene is a planar, shape-persistent macrocycle with 5-fold symmetry. A range of derivatives bearing peripheral functional groups suitable for generating supramolecular interactions has been designed and synthesised for potential applications in creating 2D quasicrystal molecular assemblies. The new campestarene derivatives bear ester, carboxylic acid, methoxy, bromo, 4-pyridyl, 4-cyanophenyl and 4-phenyl carboxylic acid groups, including further derivatives of the latter two bearing alkyl chains on the phenyl groups to improve solubility. The campestarene derivatives were prepared by reductive condensation of phenol precursors bearing nitro and formyl groups using Na2S2O4. The target functional groups were installed either by pre-cyclisation derivatisation or by synthesis of methoxy-substituted campestarene and subsequent derivatisation. The cyclisation reaction is tolerant of the functional groups introduced. The ten new campestarene derivatives were characterised by NMR spectroscopy and MALDI-TOF MS, although the poor solubility of some examples precluded their detailed characterisation.

3-substituted coumarin derivative and application and GPR35 receptor agonist

The invention discloses a 3-substituted coumarin derivative and a pharmaceutically acceptable salt, a solvate, a hydrate or a crystal form. The compound of the invention generally exhibits high agonistic activity against human G protein-coupled receptor 35 (GPR35) and is specific agonists of the human GPR35 receptor. The compound provided by the invention is an active ligand of the novel GPR35 receptor, and the compound and the pharmaceutically acceptable salt, the solvate, the hydrate or the crystal form thereof generally exhibit higher activity and good selectivity to the human GPR35. The 3-substituted coumarin derivative is the specific agonist of the GPR35 receptor and can be used in the preparation of a medicament for treating, preventing and inhibiting a disease mediated by the GPR35receptor.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Crystal structures, spectroscopic, electrochemical, and antibacterial properties of a series of new copper(II) Schiff base complexes

Two new and two previously reported Schiff base ligands as well as four corresponding new Cu(II) complexes (CuL1-4) were synthesized and characterized. The Schiff base ligands were synthesized from condensation of 5-bromo-2-hydroxy-3-nitrobenza

Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one

The present invention relates to an extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates

1-[2H-1-BENZOPYRAN-2-ONE-8-YL]-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN

The invention relates to a novel use of known 1-[2H-1-benzopyran-2-one-8-yl]--piperazine derivatives, broad spectrum 5-HT receptor binding compounds, having amongst other functional serotonin receptor activities, potent 5-HT1A-agonistic as well

1-[2H-1-BENZOPYRAN-2-ONE-8-YL]-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF MOVEMENT DISORDERS

The invention relates to a novel use of known 1-[2H-1-benzopyran-2-one-8-yl]-piperazine derivatives, broad spectrum 5-HT receptor binding compounds, having amongst other functional serotonin receptor activities, potent 5-HT1A receptor agonistic

PROCESS FOR THE PREPARATION OF 3-AMINO-8-(1-PIPERAZINYL) -2H-1-BENZOPYRAN-2-ONE AND SALTS AND HYDRATES THEREOF

The invention relates to a novel process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one, a broad spectrum 5-HT receptor binding ligand having potent 5-HT1A-agonistic as well as 5-HT1D-antagonistic activity. The invention also relat

Total synthesis of the marine alkaloid halitulin

The structure of the strongly cytotoxic marine alkaloid halitulin (1) has been confirmed by total synthesis and its absolute configuration determined as (15S). The synthesis follows a strategy previously reported by one of us and uses an efficient prepara